Drug Profile

Secukinumab - Novartis

Alternative Names: AIN-457; Anti-interleukin 17A monoclonal antibody; Cosentyx; KB-03303A; Kosentikusu; NVP-AIN-457; Scapho

Latest Information Update: 23 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alcon; Novartis
Developer Beth Israel Deaconess Medical Center; GWT-TUD GmbH; Icahn School of Medicine at Mount Sinai; Novartis
Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
Mechanism of Action IL17A protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Non-radiographic axial spondyloarthritis
New Molecular Entity Yes

Marketed Ankylosing spondylitis; Hidradenitis suppurativa; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
Registered Juvenile rheumatoid arthritis
Preregistration Polymyalgia rheumatica
Phase III Graves ophthalmopathy
Phase II Atopic dermatitis; Discoid lupus erythematosus; Necrobiosis lipoidica; SARS-CoV-2 acute respiratory disease; Tendon injuries
Discontinued Alopecia areata; Asthma; Crohn's disease; Dry eyes; Giant cell arteritis; Lichen planus; Lupus nephritis; Multiple sclerosis; Rheumatoid arthritis; Rotator cuff injuries; Type 1 diabetes mellitus; Uveitis

18 Sep 2026 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopts positive opinion for secukinumab in polymyalgia rheumatica (PMR) (Treatment-experienced, Combination therapy)
30 Jul 2026 Novartis Pharmaceuticals plans a observational trial for Axial spondyloarthritis and Ankylosing spondylitis (SC) in September 2026 (NCT07737730)
15 Jul 2026 Novartis Pharmaceuticals completes a phase III trial for Hidradenitis suppurativa in USA, Australia, Austria, Belgium, Bulgaria, Canada, Colombia, Czech Republic, France, Germany, Greece, Guatemala, Hungary, India, Israel, Italy, Japan, Lebanon, Lithuania, Malaysia, Mexico, Netherlands, Philippines, Poland, Portugal, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Turkey, Vietnam and United Kingdom (NCT04179175) (EudraCT2019-003230-17)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com